DYV800 / Dyve Biosci, H. Lee Moffitt Cancer Center and Research Institute - LARVOL DELTA

Effect of transdermal bicarbonate buffer therapy on tumor acidity and CD8 T cell responses in bladder cancer (SITC 2024) - "Control mice were untreated, while the treated group received topical application of 100ul of DYV800 bicarbonate cream 2x/day...Hence, transdermal buffer therapy has great potential to enhance anti-tumor immune responses. Combining strategies that neutralize acidity at the tumor site with other regimens to improve T cell responses has great potential to enhance immunotherapy."

IO biomarker • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • CD69 • CD8

Dyve Biosciences Presents Preclinical Data from Lead Oncology Drug Candidate, DYV800, at the American Association for Cancer Research 2023 Annual Meeting (Businesswire) - "Dyve Biosciences, Inc...announced the summary results of a poster presentation from the on-going preclinical partnership with the H. Lee Moffitt Cancer Center & Research Institute ('Moffitt') showing preclinical data from the company’s unique delivery approach that unlocks the powerful effects of neutralizing the TME acidity. The poster, presented in collaboration with Moffitt, showcased data demonstrating the delivery of intuitive, targeted pH modulation to treat solid tumors....In the presentation, Dyve and Moffitt demonstrated for the first time that the extracellular pH of tumors can be increased upon application of a buffer formulation delivered transdermally, bypassing the GI tract and unlocking a more viable route to TME buffering therapy in oncology."

Preclinical • Oncology • Solid Tumor

Transdermal alkalinization treatment induces pH changes in a murine melanoma model as measured with MRI-CEST pH imaging (AACR 2023) - "These experiments demonstrate for the first time that the extracellular pH of tumors can be increased upon application of a buffer formulation transdermally delivered to mice. Future experiments are expected to provide insights into the effect of DYV800 cream application on tumor growth and immune cell migration and activation in the tumor microenvironment."

Preclinical • Melanoma • Oncology • Solid Tumor

Dyve Announces Poster Presentation at 2023 AACR Annual Meeting (Businesswire) - "Dyve Biosciences...announced that preliminary data from the ongoing pre-clinical partnership with the H. Lee Moffitt Cancer Center & Research Institute will be presented at a poster presentation at the upcoming American Association for Cancer Research (AACR) annual meeting, taking place April 14-19, 2023, in Orlando, Florida....Dyve will present pre-clinical data from its lead oncology drug candidate, DYV800, a pH modulating agent that targets tumor microenvironment (TME) acidity in solid tumors."

Preclinical • Oncology • Solid Tumor